Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

We Doctor

    • Home
    • We Doctor
Company Deals

We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 31, 2024

China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital...

Company Deals

Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives

Fineline Cube Sep 23, 2024

We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing...

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.